The patent generally claims methods for treating Alzheimer’s disease comprising administering scyllo-inositol (ELND005). The patent will expire in the year 2025 or later due to any patent term extensions.
In 2006, Elan and Transition entered into an exclusive, worldwide collaboration agreement for the joint development and commercialization of ELND005 for the treatment of Alzheimer’s disease and other indications.
Tony Cruz, chairman and CEO of Transition, said: “The issuance of this patent is an important milestone in the development of ELND005, a unique oral compound with a favorable safety profile that crosses the blood-brain barrier and targets the disaggregation of amyloid beta in the brain.”